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Site.directed mutagenesis of two sets of three periodic Iea¢ine residues which appear at every seventh position in the C-terminal region of human 
interleukin-6 (IL-6) was performed. Both receptor-binding and immunoglobalin (lg).induetion activities of a triple mutant Leu'~'t~.~m-~Yal were 
only 1% compared with those of wild.typ~ IL-6. However, th~ mutant Leu~Zm.t~Va~ had 13% receptor.bindlng and 2% lg-induction activities 
of those of wild-type IL-6. In order to obtain more direct information on the receptor-binding region, we p~pared two synthetic peptidcs. A 
significant binding activity was observed for the l~ptide Lca~S-Met ~,  but not for the peptide Leu~-Arg ~. These results indicate that leu¢ine 
residues in the C-terminal region, especially Leu ~, Lea m, and Lea ~:, play an import~m role in the receptor.binding and lg-induction activities. 
lntorleukin 6; Site-din.~eted mutagenesis; Peptide fragment; Receptor-binding activity; B-Ceil stimulator/activity; Human 
1. INTRODUCTION 
Interleukin-6 (IL-6) is important in modulating 
growth and differentiation f various cells [1]. Comple- 
mentary DNA encoding human IL-6 (M~ = 21,000) has 
been isolated [2] and recombinant IL-6 has been ex- 
pressed at a high level in Escherichia coli (E. eolO [3]. 
Only after the binding of IL-6 to its receptor [4] on the 
cell surface, can the receptor associate with a non-ligand 
signal transducer, gpl30, and mediate its function [5]. 
Soluble human IL-6 receptor, which lacks the trans- 
membrane and intraeytoplasmic domains, has been ex- 
pressed in Chinese hamster ovary cells [6]. 
Structure-function relationship of human IL-6 has 
been examined by producing IL-6 mutants and estab- 
lishing a monoclonal antibody clone specific for IL-6. 
Brakenhoff et al. prepared various IL-6 mutants with 
deletions in the N-terminal re ,on a~d concluded that 
the first 28 amino acid residues can be removed without 
significantly affecting the biological activity [7]. Arcone 
et al. tried internal deletions of IL-6, and concluded that 
only residues 29-34 are essential for the biological activ- 
ity [8]. Ida ¢t al. prepared a monodonal antibody that 
strongly neutralizes the biological activity, and showed 
that the antibody r~cognizes the epitope comprising see- 
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ment Thr~°-Phet7~ [9]. Krtattgen et al. showed that re- 
moval of only three amino acids from the C-terminal 
region of IL-6 led to a complet~ loss of the biological 
activity [10]. However, it is still not clear which seg- 
ments of IL-6 are actually involved in the receptor- 
binding. 
In the previous tudy, on the basis of the chemical 
modification and ~H NMR data, we have concluded 
that Trp ~,  Met ~62, His ~65, and Met ta~ are in spatial 
proximity, comprising the receptor-binding region [11]. 
Furthermore, we have prepared several IL-6 mutants 
and suggested that hydrophobie side chains existing in 
Leu ~9, Met ~62, and Leu mc~ are significantly involved in 
the receptor-binding of IL-6 [12]. In the C.terminal re- 
gion of human IL-6, there are two sets of three periodic 
Leu residues which appear at every seventh position, i.e. 
Leu I~-', Leu l~°, Leu t~ and l.~u 1c~, Lcu 17~, Lcu ta~ (Fig. 1). 
In the present study, on the basis of our previous find- 
ings, we have tried two sets of triple mutations 
Loul~2'i~9'160---~Val andLeu168'175'ts2--)Val and discussed 
the role of hydrophobie side chains of the l.zu residues 
in the receptor-binding and immunoglobulin (lg)-induo- 
tion activities. We have also prepared two peptides, 
Leut~-%Arg 169 and Leu~6LMet ~ss, corresponding to two 
sets of triple mutations (Leu~t~9'm~Val and 
I.gu ~6a,~vS,~a~--->Val), respectively, and measm~t their r~- 
ceptor-binding activities. 
2. MATERIALS AND METHODS 
2.1. Oligonueleottde.dtrected mutagenesLs 
The nautagenic oligonucleotides were synth~izcd by pho~pho- 
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ramiditc hemistry on an Applied Biosystems Model 38lA synthesizer 
and purified on oliponuclrotide purification cartridges. The various 
mutagenic oligonucleotides for construction of the IL-6 mutanls were 
used (Fig. 1). The 1,000~base pair Kp&.Sall fragment derived from 
pBSF7.38-1 [3], coding human lL-6 (185 amino acids), was subcloned 
into M I3mpl9, and the single-stranded form of this plasmid was used 
as a template for mutagenesis. The mutagenesis was performed by 
using an oligonucleotide-directed in vitro mutagenesis system (Amer- 
sham) [13]. The nucleotide sequence of mutant clones was determined 
by dideoxynucleotide chain termination procdurr: to ensure that there 
were no other point mutations [14]. For IL-6 protein expression, 
mutagenic DNA wns recloned into E. colt’ expression vector derived 
from pBSF2.38-1. 
2.2. Protein expression and pw$htiott 
All mutant and wild-type IL-69 were produced as described by 
Yasukawa et al. with some modifications [15]. The E. coii RB791 
containing the plasmid coding IL-6s was cultured for 5 h by using LB 
medium (60 ml). The cells were harvested by centrifugation, and the 
cell pellet was suspended in 50 mM Tris-HCl (pH 8.0) and disruptcrl 
by sonication. After centrifugation, the inclusion body of human 
growth hormone (hGH)-IL-6 fusion protein in the pellet fraction was 
dissolved with 8 M urea in 50 mM Gly-NuOH buffer (pH 9.0). The 
protein solution was dialyzed against I M urea in 50 mM Tris-HCI 
(PI-I 8.0) in the presence of a glutathione redox system. and the resul- 
tant refolded fusion protein was cleaved by thrombin into hGH and 
IL-6. Afier the addition of 20 mM CaCI,. the solution was centrifuged, 
and the resultant pellet was dissolved by 6 M guanidine-HCl in 50 mM 
Tris.HCI (pH 8.0). The IL-6 solution was dialyzed against IO mM 
Tris-HCI buffer (pH 8.0) in the presence of the glutathione redox 
system. Wild-type and mutant 1L.6~ were purified by ammonium 
sulfate precipitation, and apparent 21 kDa single band was observed 
by SDS~polyacrylomide gelelectrophoresis. From 60 ml of culture 
medium , 200-SO0 ,ug of wild-type and mutant IL-6s was obtaind. 
Protein concentrations of IL-6s was obtained. Protein concentrations 
ol’ IL-6s were determintxl by the dye binding assay (Bio-Rod Labora- 
tories) with bovine serum albumin as a srandard. 
2.3. Rnclioisotope competirive assay for testing the bh&itg activity of 
IL-6 ntutfmts 
Anti-(IL-6 receptor) &body (4 pdrnl) 1161 was cuated in the 9G- 
well microplates in lOO,U of 0.1 M carbonate/hydrogen carbonate (pH 
9.6) at 4OC overnight. The wells were blocked with 1% bovine serum 
albumin in XJ mM phosphate, 120 mMNaC1 (pH 7.4) nt room temper- 
ature for 2 h. Soluble IL-6 receptor (IO ng) [6] was added and incu- 
bated l’or 2 h. After washing, 100 ~1 of test samples containing ‘?‘I- 
labeled IL-6 (15.000 cpm) was incubated at room temperature for 2 
h. The wells were washed and radioactivity of each well was measured 
with a y-counter (Alokn). 
2.4. &ceU stimtikttory assay 
Four thousand SKW6-CL4 cells, EBV-transformed B-cell lines, 
were cultured in 200 ,ul of RPM11640 medium containing 10% fetal 
calf serum, and wild-type and mutant IL-6s were added into the 
culture medium [17]. After three days, the concentration of IgM pro- 
duced in the culture medium was determined by enzyme-linked im- 
munosorbcnt assay (ELISA). 
2.5. Sytrtitesis of peptkic fragments 
Peptide fragmenls, Leu’s2.Arg’” and Leu16ti.Met’m5, were synthe- 
sized using an Applied Biosystems Model 430A peptidc synthesizer. 
Crude peptides were washed with diethylether, extracted with acetic 
acid, and lyophilized. PuriIication was carried out by reverse-phase 
high performance iiquid chromatography. The amino acid composi- 
tion of each peptide was checked. The whole amino acid sequence of 





The competitive binding activities of wild-type and 
mutant IL-6s to its soluble receptor were measured by 
using [“51]IL-6. The radioactivity derived from bound 
[‘~sI]IL-G decreased with increasing concentration of the 
competing IL-5 analogs and generated the competition 
binding curves as shown in Fig. 2. More pronounced 
efkcts on the binding activity were observed with mu- 
tant ~~,,168,175.182+~~~ than with mutant 
Leu15’~‘5Y*‘“6+Val. The amount of wild-type and mutant 
IL-6 proteins required for 50% displacement of [?]IL- 
6 (IC,,) was determined for each IL-6 analogs (Table I). 
The binding activities of mutants Leu’s’*1s9*1G6+Val and 
Leu1G8~175*1a~~Val were 13% and 1% compared with that 
of wild-type IL-G, respectively. 
The biological activities of IL-6 analogs were esti- 
mated by the amount of IgM produced from IL-Qana- 
log-treated SKW6-CL4 cells (Fig:. 3). Both mutants 
L~u’~~~‘~‘*‘~~-+V~~ and Leu’68*‘7s*‘8z+Val showed a pro- ” 
nounced decrease in the &-induction activity. The 
amount of IL-6 analogs required for the half-maximal 
Ig-induction activity (EC,,) was determined for each 
IL-6 analog (Table I). The Ig-induction activities of 
mutants Leu’5’*‘59~‘G6+Val and Leu’68~175*18~+Val were 
2% and 1% of that of wild-type IL-6, respectively. 
Since the receptor-binding activity of mutant 
Leu1Gs~17s~1”‘+Val was 13-fold less than that of mutant 
Leu r5’S’59*166+Val, we have focused our at&i&n on the 
former Leu residues, Leula, Leui75, and Leu’82 (Table 
I). The receptor-binding activities of mutants 
Leu168+Val, Leu’75+Val, and Leuis2+Val, were 20%, 
8%, and 17% of that of wild-type IL-6. This result shows 
(b) 
(1) &CTckccum.$ (Lou’” - #rl) 
(2) 6QccAGT~~(Lou’” -m, 
(3) s-Mxuc- TKXaX-3QU~-#r) 
(4) ~TCXAl-lXT UOQCUQCTTTn-3”(LaUW-VY)=-vU) 
IS) 6znTAkoQMTToo7 ~-3’(laU’R-U) 
(6) sXcT~~TG-3’I~“1-~) 
Fig. 1. Amino acid sequence in the C-terminal region of human IL-6 
(a) and mutagenic oligonucleotides designed for site-directed mut- 
agenesis (b). 
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Fig. 2. The competitive binding activity to the soluble IL-6 receptor of wild-type (8). mutmt Leu ‘szA1w*‘m+Vnl (A), ilnd mutant Let~‘~~“~*‘~+Val 
(a). The immunosorbcnt assay was performed as drtscribed under Materials and Methods. Radioactivities of [‘z5r]lL6 binding to soluble IL-6 
receptor were measured by a y-counter. Data represent means of triplicate assays. 
that Leu:; ’ plays the most important role in the recep- 
for-binding of IL-6. More significant effects on the I%- 
ceptor-binding activity were observed for double substi- 
tutions of Leurfi8, Leu”15, and Leu”’ than the single 
substitutions. Mutants Le~~~~~~~~-+Val and 
Leu’75*‘8z+Val showed 3% and 6% receptor-binding ac- 
tivities of that of wild-type IL-6. The decrease in the 
Ig-induction activity induced by single or double substi- 
tutions of Leu’(“, Leu”‘, or Lcu’“~ was consistent with 
that of the receptor-binding activity. 
Table I 
Amino acid substitutions and the receptor-binding and Ig-induction 
aclivities 
Substitutions Relative activity 
Receptor-binding Iginduction activity 




Leu’“%Val 20 33 
Leu’7s-tVal 8 13 
Leu’GVal 17 19 
3 2 
6 I 
‘The amount of IL-6 analogs required ior 50% dispiucemcnt of 
[‘Y]lLd was determined. 
“The amount of lL-6 analogs rquired for the half-maximal Ig-induc- 
tion activity was determined. 
In order to show that the C-terminal region is directly 
involved in the receptor-binding, twa peptides, LeuiSz- 
Arg’69 and Leu16S-Met’85, were synthesized. A signifi- 
cant activity of the receptor-binding was observed for 
the peptide Leu’6s-Met’85 (Fig. 4). On the basis of the 
KS0 value, the activity of the peptide Leur6’-MetiE was 
estimated as 10”-fold less than that of wild-type IL-6. 
Fig. 3. The Ig-induction activity of wild-type (m), mutant 
?z~‘~~‘~‘*‘~+Ve! (A), and mutant Le~‘~‘~~~‘%Val (0). The assay 
was performed as described under Mavxials and Melhods. The 
amount of IgM produced from SKW6-CL4 cells was meaaured by 
ELISA. Data represent means of triplicate assays. 
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Fig. 4. The competitive binding activity to the soluble IL-6 receptor 
of intact IL-6 (a). and ryuthetic peptides. Lct1’“~-4r@” (b) and Leu’“- 
MetIs (0). The immunosorbent assay was perfo&d as described 
under Materials and Methods. Radioactivities of [‘“51]1L-6 binding to 
soluble IL-6 receptor were measured by a r_counter. Data represent 
means of triplicate assays. 
No receptor-binding activity was observed for the pep 
tide Leu’52-Arg*69. 
4. DISCUSSION 
On the basis of the crystal structure cf hGH [18], 
Bazan proposed a model of IL-6 folding comprising 
bundles of four antiparallel helices A, B, C, and D [19]. 
Helix D (Gln’5S-Met’gS) in the C-terminal region of IL-6 
was suggested to play an important role in the receptor- 
binding [11,20]. In the C-terminal region of human IL- 
6, there are two sets of three periodic Leu residues which 
appear at every seventh position. This suggests an in- 
triguing possibility that helix D composes one side of 
the leucine zipper structure [21]. A significant decrease 
in DNA-binding activity has previously been reported 
for substitutions with Val residues of Leu residues that 
exist at every seventh position in the leucine zipper re- 
gion [22-241. On the basis of these results, we tried 
substitutions of Leu’52, Leu15’, L~u’~~, L~u’~~, and 
L~u’“~ with Val residues of IL-6. The receptor-binding 
activity of mutant Leu ‘68*‘75*‘8Z+Val is only 1% com- 
pared with that of wild-type IL-6 and 13-fold less than 
that of mutant Leu’5Z*1S9*‘66+Val. This suggests that the 
hydrophobic side chains of Leu residues in the C-termi- 
nal region, especially Leu“j’, Leu’75, and Leu’s2, play an 
important role in the receptor-binding. Among three 
single mutations, the single substitution of Leu’75+Val 
was most effective in reducing the receptor-binding ac- 
tivity. This is consistent with the following two results. 
(i) Leu17’ in IL-6 molecule is all conserved among other 
helical cytokines, such as GH, prolactin, erythropoietin, 
granulocyte-colony-stimulating factor, and myelomon- 
ocytic growth factor. (ii) It was concluded by alanine- 
scanning mutagenesis of hGH [20] that mutation of 
Thr17’ or Phen6, which is near Leu’77 corresponding to 
Leu’75 in IL-6, is most effective on the receptor-binding. 
On the basis of the mutagenesis studies of human IL-6, 
we propose that helix D composes the leucine zipper 
structure. The dimer formation of IL-6 molecule is sug 
gestcd by Rose-John et al. [25]. However, it is still un- 
clear whether the hydrophobic interaction between two 
helices which participate in the formation of the leucine 
zipper structure would be intermolecular or incramo- 
lecular. 
The Ig-induction activity is observed to be more sus- 
ceptible to the substitutions of Leu’52*‘59*‘“+Val than 
the receptor-binding activity, whereas both activities are 
shown to be equally susceptible to the single, double, 
and triple substitutions of Leu16’, Leu’75, and Leuls2. 
VI.___ ^ __._ Ir, _*--__-. *l-r T ,..IS? 11,030 IF;JUI,J JuggG;r& CILLIL Lb&& , LrP, aI:! Leu’M 
play a role not only in the receptor-binding but also in 
other mechanisms involved in the Ig-induction activity. 
It is possible that some residues existing in the Leuls2- 
Leu’66 region are involved in the interaction of IL-6 with 
a signal transducer, gp130. By uncoupling the receptor- 
binding and biological activities, it should be possible, 
in principle, to design IL-6 antagonists. 
We have concluded that Leu16’, L~u’~~, and Leu18’ 
play a more important role in the receptor-binding ac- 
tivity than Leu”‘, LeuIs9, and Leu’66. In order to obtain 
more direct information on the receptor-binding region, 
we prepared two peptides, Leu’52-Arg’69 and Leu16’- 
Metls5. A significant activity of receptor-binding was 
observed for the peptide Leu’68-Met’85, but not for the 
peptide Leu ‘5Z-Arg’69. These results not only support 
that L.~u’~~, Leu’7S, and Leuls2 existing in the peptide 
Leu’68-Met’85 are important in binding of IL-6 to its 
receptor, but also directly show that the peptide Leu’“‘- 
Met’*’ comprises a part of the receptor-binding region. 
The peptide Leu ‘6a-Met’s5 has a much lower activity of 
receptor-binding than intact IL-6, probably because the 
peptide fragment cannot take the same tertiary struc- 
ture as the corresponding region which exists in intact 
IL-6. 
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